GILD AI Stock Analysis – Buy, Hold, or Avoid?
Gilead Sciences, Inc. (GILD)
Gilead Sciences (GILD) offers a compelling investment case, combining a resurgent growth profile, robust margins, and a strong technical uptrend, all supported by positive sentiment and fair valuation. While moderate regulatory and competitive risks persist, the company’s dominant HIV franchise, expanding oncology pipeline, and consistent earnings execution provide a solid foundation for both near- and long-term investors.
Fundamentals
Gilead Sciences (GILD) exhibits robust financial health, with notable revenue and income growth in 2025 supported by strong operating performance and improved profitability. The company has delivered several consecutive quarterly beats on both EPS and revenue estimates, signaling operational momentum and management's strong execution.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
4.70% YoY
Q4 2025
Net Income
22.43% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.9B | 7.8B | 7.1B | 6.7B | 7.6B | 7.5B | 7.0B | 6.7B |
| Revenue Growth YoY | +4.70% | +2.97% | +1.84% | -0.28% | +6.40% | +7.02% | +5.36% | +5.26% |
| Net Income | 2.2B | 3.1B | 2.0B | 1.3B | 1.8B | 1.3B | 1.6B | -4.2B |
| Net Income Growth YoY | +22.43% | +143.58% | +21.44% | +131.53% | +24.77% | -42.52% | +54.45% | -512.87% |
| EPS | $1.76 | $2.46 | $1.57 | $1.06 | $1.43 | $1.00 | $1.29 | -$3.34 |
| EPS Growth YoY | +23.08% | +146.00% | +21.71% | +131.74% | +24.35% | -42.86% | +53.57% | -512.35% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.84% | 79.80% | 78.80% | 76.90% | 79.11% | 79.14% | 77.79% | 76.79% |
| Operating Margin | 37.40% | 42.82% | 34.94% | 33.55% | 32.40% | 11.77% | 38.03% | -64.64% |
| Net Margin | 27.55% | 39.28% | 27.68% | 19.72% | 23.56% | 16.61% | 23.21% | -62.37% |
| Return on Equity (ROE) | 9.65% | 14.17% | 9.96% | 6.86% | 9.22% | 6.78% | 8.83% | -23.78% |
| Return on Assets (ROA) | 6.47% | 9.46% | 6.80% | 4.57% | 5.80% | 4.88% | 7.19% | -16.99% |
Technical Analysis
GILD is currently in a strong uptrend, exhibiting a bullish technical setup with price well above its key moving averages and a confirmed golden cross. Momentum is positive, supported by an ADX above 35, indicating a strong trend, while the RSI remains neutral, suggesting room for further upward movement. The stock is in the advancing Stage 2 phase, signaling institutional accumulation and favorable buying conditions.
No extreme reading
Price in uptrend
Strong trend active
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Gilead Sciences (GILD) exhibits robust financial health, with notable revenue and income growth in 2025 supported by strong operating performance and improved profitability. The company has delivered several consecutive quarterly beats on both EPS and revenue estimates, signaling operational momentum and management's strong execution.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$1.86
Estimated
$1.81
Surprise
+$0.05
Surprise %
+2.76%
Revenue
Actual
$7.93B
Estimated
$7.69B
Surprise
+$234.64M
Surprise %
+3.05%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $1.86 | $2.47 | $2.01 | $1.81 | $1.90 | $2.02 | $2.01 | $-1.32 |
| EPS (Estimated) | $1.81 | $2.13 | $1.96 | $1.78 | $1.74 | $1.53 | $1.61 | $-1.49 |
| EPS Surprise | +$0.05 | +$0.34 | +$0.05 | +$0.03 | +$0.16 | +$0.49 | +$0.40 | +$0.17 |
| % Diff | +2.8% | +16.0% | +2.6% | +1.7% | +9.2% | +32.0% | +24.8% | +11.4% |
| Revenue | ||||||||
| Revenue (Actual) | $7.93B | $7.77B | $7.08B | $6.67B | $7.57B | $7.55B | $6.95B | $6.69B |
| Revenue (Estimated) | $7.69B | $7.45B | $6.98B | $6.81B | $7.15B | $7.02B | $6.7B | $6.36B |
| Revenue Surprise | +$234.64M | +$323.62M | +$99.5M | -$143.87M | +$416.55M | +$529.36M | +$246.47M | +$328.91M |
| % Diff | +3.1% | +4.3% | +1.4% | -2.1% | +5.8% | +7.5% | +3.7% | +5.2% |
Valuation
Gilead Sciences (GILD) currently trades at moderate valuations with strong profitability metrics, reflecting solid earnings growth and operational efficiency amid a stable revenue environment. Analysts generally maintain a positive outlook with a consensus "Buy" rating and price targets suggesting mild upside potential. Compared to healthcare peers, GILD balances attractive margins with reasonable leverage, supporting a fairly valued stance in the sector.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 17.46 | 11.30 | 17.61 | 26.54 | 16.16 | 20.86 | 13.26 | -5.45 |
| Price to Sales | 19.24 | 17.76 | 19.49 | 20.94 | 15.23 | 13.86 | 12.31 | 13.59 |
| Price to Book | 6.74 | 6.41 | 7.02 | 7.29 | 5.96 | 5.66 | 4.68 | 5.18 |
| Enterprise Value to EBITDA | 72.64 | 33.95 | 46.78 | 60.13 | 42.65 | 65.16 | 35.58 | -31.44 |
| Enterprise Value to Revenue | 21.38 | 20.03 | 22.29 | 23.49 | 17.52 | 16.27 | 15.27 | 16.66 |
Sentiment & Analyst Ratings
Gilead Sciences (GILD) currently exhibits a broadly positive market sentiment, buoyed by strong analyst support and solid recent financial performance. News coverage emphasizes strategic acquisitions, robust HIV treatment data, and dividend growth, which bolster confidence among investors. Social sentiment is less defined but appears stable, with retail focus on GILD's fundamentals and pipeline developments.
Analyst Recommendations
Risk Assessment
Gilead Sciences maintains a solid financial base supported by a strong HIV franchise and expanding oncology portfolio, though it faces significant regulatory and competitive risks, including FDA clinical holds and pricing pressures from recent healthcare legislation. Liquidity and solvency metrics indicate adequate financial health, but regulatory scrutiny and competitive dynamics temper near-term growth prospects. Market sentiment is cautiously optimistic, balancing solid cash flow and dividend prospects against challenges in clinical programs and pricing uncertainties.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 1.68 | 1.45 | 1.32 | 1.37 | 1.60 | 1.26 | 1.14 | 1.08 |
| Quick Ratio | 1.31 | 1.31 | 1.15 | 1.23 | 1.45 | 1.10 | 0.95 | 0.94 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 1.09 | 1.16 | 1.27 | 1.30 | 1.41 | 1.26 | 1.28 | 1.44 |
| Debt-to-Assets | 0.42 | 0.43 | 0.45 | 0.44 | 0.46 | 0.43 | 0.44 | 0.45 |
Liquidity Assessment
Current Ratio: 1.68(Strong)
Quick Ratio: 1.31(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 1.09(High)
Debt-to-Assets: 0.42(Moderate)
The company has relatively high debt levels, which may increase financial risk in economic downturns.
Frequently Asked Questions about GILD
AI Answers: Common Questions About GILD
Get AI-powered answers to the questions investors ask most about Gilead Sciences, Inc.
Yes, GILD is a good buy at current levels ($147.83), trading at a P/E of 18.14 and showing strong revenue and EPS growth in 2025. The stock is in a bullish technical setup, with analyst price targets averaging $156 and fundamentals supporting further upside.
Unless your thesis has changed or you need to rebalance, there is no strong reason to sell now. Fundamentals are improving, technicals are bullish, and sentiment is positive; only consider trimming if GILD approaches major resistance ($157.29) and momentum stalls.
The biggest risks are regulatory delays (e.g., FDA clinical holds), pricing pressure from the Inflation Reduction Act, and competitive threats in HIV/oncology. Sentinel notes a moderate risk level, with a debt-to-equity ratio near 1.1 and interest coverage at 11.6x supporting financial stability.
Short-term resistance is at $157.29 (52-week high), with analyst targets averaging $156 and some as high as $177. Support levels are $136.40 (50 SMA) and $120.61 (200 SMA); a breakout above $157 could open further upside.
GILD is fairly valued with a P/E of 18.14 and EV/EBITDA in line with sector peers. Its strong operating margin (~40%) and free cash flow margin (>30%) justify current multiples, with no signs of overvaluation.
GILD is fundamentally strong, with 2025 revenue up 23.9% YoY, net margin at 28.9%, and gross margin near 87%. The balance sheet is healthy, with a current ratio above 1.6 and robust free cash flow supporting ongoing R&D and dividends.
Technical analysis is bullish: price is above the 50/200 SMA (golden cross), ADX at 35.58 confirms trend strength, and RSI at 54.2 suggests more upside before overbought conditions. Key resistance is $157.29, with support at $136.40.
Key catalysts include upcoming earnings reports, clinical trial results (especially in oncology and HIV), regulatory decisions, and potential new product launches. Dividend increases and strategic acquisitions (e.g., Arcellx) are also positive drivers.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.